Tests pegozafermin in adults with liver scarring from fatty liver disease
Tests pegozafermin against placebo in adults with compensated cirrhosis from MASH.
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Akron, Albany, Albuquerque, Amarillo, Ann Arbor, Asheville, Athens, Atlanta, Austin, Baltimore, Bellevue, Birmingham, Brownsville, Burlington, Camarillo, Canoga Park, Chandler, Charleston, Charlotte, Chicago, Cincinnati, Clermont, Cleveland, Clinton Township, Columbia, Columbus, Cordova, Coronado, Dayton, DeSoto, Detroit, Durham, East Greenwich, Edinburg, Farmers Branch, Fayetteville, Flagstaff, Florham Park, Flowood, Fort Myers, Fort Worth, Fountain Valley, Framingham, Fresno, Gainesville, Georgetown, Glen Burnie, Glenview, Greenbelt, Greenville, Hammond, Harlingen, Hermitage, Hialeah Gardens, Homestead, Homewood, Houston, Huntington Park, Iowa City, Jacksonville, Kansas City, La Jolla, Lady Lake, Lafayette, Lake Charles, Lakewood Rch, Las Vegas, Lehigh Acres, Lewisville, Liberty Township, Little Rock, Littleton, Los Angeles, Louisville, Lubbock, Maitland, Mansfield, Marietta, Miami, Minneapolis, Nashville, New Albany, New Port Richey, New York, North Little Rock, Ocala, Ocoee, Orlando, Pasadena, Pearland, Peoria, Philadelphia, Phoenix, Pittsburgh, Poway, Rapid City, Redwood City, Rialto, Richmond, Rochester, Sacramento, San Antonio, San Marcos, Sandy City, Santa Ana, Seattle, Somers Point, South Bend, Southlake, St Louis, Sun City, Tacoma, Topeka, Tucson, Tupelo, Tyler, University Park, Viera, Waco, West Jordan, West Monroe, Westlake, Winston-Salem, Winter Park, Wyoming, and Ypsilanti, United StatesSee the 126 sitesAlso in 24 other countries, 151 sites
- Trial code
- NCT06419374
- EU 2023-510395-31-00
- U1111-1300-7189
- Registry title
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,800 people, planned
- Started
- 24 May 2024
- Expected to end
- 31 Aug 2031
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Pegozafermin
- Placebo
- Record updated
- 23 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with compensated cirrhosis (scarred liver that still works) caused by MASH (fatty liver disease linked to metabolism). The cirrhosis and MASH must be confirmed.
- Age
- 18 to 75 years
- Sex
- All sexes. Women must not be pregnant.
- Disease stage
- Compensated cirrhosis due to MASH, shown by a liver biopsy (historical or at screening) and by a clinical test-based (NIT) diagnosis of cirrhosis.
- Earlier treatment
- People taking vitamin E (more than 400 IU per day) must have been on a stable dose for at least 6 months before screening.
- Biomarker or test result
- Type 2 diabetes diagnosed at least 3 months before screening, or at least 2 metabolic risk factors.
Main reasons for not taking part
- A liver disease other than MASH
- Past or current signs of hepatic decompensation (the liver no longer coping)
- Past or current liver cancer (hepatocellular carcinoma)
- Type 1 diabetes or poorly controlled type 2 diabetes
- ALT or AST of 250 U/L or higher
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Males or non-pregnant females aged between 18 and 75 years (inclusive) at time of signing the informed consent form (ICF)
- Participants must have type 2 diabetes mellitus diagnosed at least 3 months before screening or at least 2 metabolic risk factors
- Evidence of both cirrhosis and MASH etiology, either through a historical biopsy or a biopsy at Screening
- Clinical diagnosis of cirrhosis based on the NIT algorithm
Who cannot take part
- Participants taking vitamin E (>400 international units [IU]/day) must be on stable dose for at least 6 months prior to screening; Other protocol-defined inclusion and exclusion criteria may apply
- Liver disorder other than MASH
- Have type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus
- ALT or aspartate aminotransferase (AST) ≥250 units per liter (U/L)
- History or evidence of hepatic decompensation
- History or evidence of hepatocellular carcinoma
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
Also in 24 other countries, 151 sites
- Akron, OhioHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Albany, New YorkHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Albuquerque, New MexicoHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Amarillo, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Ann Arbor, MichiganHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Asheville, North CarolinaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Athens, GeorgiaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Atlanta, GeorgiaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Austin, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Baltimore, MarylandHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Bellevue, WashingtonHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Birmingham, AlabamaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Brownsville, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Burlington, MassachusettsHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Camarillo, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Canoga Park, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Chandler, ArizonaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Charleston, South CarolinaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Charlotte, North CarolinaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Chicago, IllinoisHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Cincinnati, OhioHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Clermont, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Cleveland, OhioHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Clinton Township, MichiganHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Columbia, South CarolinaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Columbus, OhioHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Cordova, TennesseeHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Coronado, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Dayton, OhioHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- DeSoto, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Detroit, MichiganHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Durham, North CarolinaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- East Greenwich, Rhode IslandHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Edinburg, TexasHospital not named in the registryNo longer taking part
- Farmers Branch, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Fayetteville, North CarolinaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Flagstaff, ArizonaHospital not named in the registryNo longer taking part
- Florham Park, New JerseyHospital not named in the registryNo longer taking part
- Flowood, MississippiHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Fort Myers, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Fort Worth, TexasHospital not named in the registryNo longer taking part
- Fountain Valley, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Framingham, MassachusettsHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Fresno, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Gainesville, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Georgetown, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Glen Burnie, MarylandHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Glenview, IllinoisHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Greenbelt, MarylandHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Greenville, North CarolinaHospital not named in the registryNo longer taking part
- Hammond, IndianaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Harlingen, TexasHospital not named in the registryNo longer taking part
- Hermitage, TennesseeHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Hialeah Gardens, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Homestead, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Homewood, AlabamaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Houston, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Huntington Park, CaliforniaHospital not named in the registryNo longer taking part
- Iowa City, IowaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Jacksonville, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Kansas City, KansasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- La Jolla, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Lady Lake, FloridaHospital not named in the registryNo longer taking part
- Lafayette, LouisianaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Lake Charles, LouisianaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Lakewood Rch, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Las Vegas, NevadaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Lehigh Acres, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Lewisville, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Liberty Township, OhioHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Little Rock, ArkansasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Littleton, ColoradoHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Los Angeles, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Louisville, KentuckyHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Lubbock, TexasHospital not named in the registryNo longer taking part
- Maitland, FloridaHospital not named in the registryNo longer taking part
- Mansfield, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Marietta, GeorgiaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Miami, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Minneapolis, MinnesotaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Nashville, TennesseeHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- New Albany, IndianaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- New Port Richey, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- New YorkHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- North Little Rock, ArkansasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Ocala, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Ocoee, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Orlando, FloridaHospital not named in the registryNo longer taking part
- Pasadena, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Pearland, TexasHospital not named in the registryNo longer taking part
- Peoria, ArizonaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Philadelphia, PennsylvaniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Phoenix, ArizonaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Pittsburgh, PennsylvaniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Poway, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Rapid City, South DakotaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Redwood City, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Rialto, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Richmond, VirginiaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Rochester, MinnesotaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Sacramento, CaliforniaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- San Antonio, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- San Marcos, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Sandy City, UtahHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Santa Ana, CaliforniaHospital not named in the registryNo longer taking part
- Seattle, WashingtonHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Somers Point, New JerseyHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- South Bend, IndianaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Southlake, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- St Louis, MissouriHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Sun City, ArizonaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Tacoma, WashingtonHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Topeka, KansasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Tucson, ArizonaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Tupelo, MississippiHospital not named in the registryNo longer taking part
- Tyler, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- University Park, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Viera, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Waco, TexasHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- West Jordan, UtahHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- West Monroe, LouisianaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Westlake, OhioHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Winston-Salem, North CarolinaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Winter Park, FloridaHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Wyoming, MichiganHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
- Ypsilanti, MichiganHospital not named in the registryContact: 89bio Clinical Study SiteTaking people
About the trial
What the trial wants to find out
The study will assess the efficacy and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
The 2 groups in the trial
- PegozaferminTreatment being tested
- PlaceboPlacebo, for comparison
Matched placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)
- Plain-language title
- Tests pegozafermin in adults with liver scarring from fatty liver diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06419374, who can take part
- Record updated
- 23 October 2026